Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colchicine for acute gout.

N Schlesinger1, R Schumacher, M Catton

  • 1UMDNJ/Robert Wood Medical School, Department of Medicine, MEB 474, PO Box 19, New Brunswick, New Jersey 08903-0019, USA. schlesna@UMDNJ.EDU

The Cochrane Database of Systematic Reviews
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

The phenomenology of pareidolia in healthy subjects and patients with left- or right-hemispheric stroke.

Heliyon·2024
Same author

Assessing domain match and feasibility of candidate instruments matching with OMERACT endorsed domains to measure flare in knee and hip osteoarthritis.

Seminars in arthritis and rheumatism·2024
Same author

The neuropsychology and neuroanatomy of reduplicative paramnesia.

Cortex; a journal devoted to the study of the nervous system and behavior·2023
Same author

Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection.

Pathology·2021
Same author

Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort.

Epidemiology and infection·2021
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Colchicine effectively reduces pain and symptoms in acute gout, but gastrointestinal side effects are common. Its use is limited by a low benefit-to-toxicity ratio, suggesting it as a second-line therapy.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Gout is a prevalent rheumatic disease globally.
  • Colchicine is recognized for acute gout treatment but frequently causes gastrointestinal adverse events.

Purpose of the Study:

  • To assess the efficacy and safety of colchicine for acute gouty arthritis.
  • To compare colchicine against placebo and other interventions.

Main Methods:

  • Systematic review of published randomized controlled trials (RCTs) and controlled clinical trials.
  • Searched multiple electronic databases up to March 2006.
  • Data extraction and quality assessment by two independent reviewers.

Main Results:

  • One RCT (N=43) showed colchicine reduced pain by 34% and clinical symptoms by 30% compared to placebo.

Related Experiment Videos

  • Number Needed to Treat (NNT) for pain reduction was 3; for symptom reduction, it was 2.
  • All colchicine recipients experienced gastrointestinal side effects (NNH=1). No comparisons with NSAIDs or corticosteroids were found.

    • Conclusions:

    • Colchicine effectively reduces pain and symptoms in acute gout attacks.
    • Its low benefit-to-toxicity ratio restricts its use, recommending it as a second-line option.
    • Further research is needed to compare colchicine with first-line therapies like NSAIDs and corticosteroids.